Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Source: NASDAQ.COM
Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.
Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.
Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.
Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDSX
Wall Street analysts forecast BDSX stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.850
Low
20.00
Averages
30.00
High
40.00
Current: 21.850
Low
20.00
Averages
30.00
High
40.00
About BDSX
Biodesix, Inc. is a diagnostic solutions company. The Company's business includes Biodesix Lung Diagnostic Testing and Biodesix Development Services. Its Biodesix Lung Diagnostic Testing provides lung diagnostic testing services for healthcare providers through five blood-based tests. Its Biodesix Development Services supports global biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that enable the development of diagnostic tests, tools, and therapeutics. The Company offers Nodify Lung tests and IQLung tests that assess cancer risk and provide treatment guidance following a lung cancer diagnosis. The Nodify Lung tests include Nodify CDT and Nodify XL2 tests, which evaluate the risk of lung cancer in lung nodules. The GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests are used in the diagnosis of lung cancer to detect tumor mutations and assess the patient’s immune system status.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elevance Health Sues CMS Over Medicare Advantage Ratings
- Lawsuit Background: Elevance Health has filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS), alleging unfair adjustments to a competitor's Medicare Advantage Star Ratings after finalization, claiming this created an uneven competitive landscape.
- Financial Impact: Elevance estimates that the disputed CMS decision cost it approximately $115 million in Medicare Advantage quality bonus payments, directly affecting its financial performance and market competitiveness.
- Industry Implications: Should the court side with Elevance, CMS may be compelled to revisit its ratings process, potentially impacting payments and competitive positioning across the industry, which could lead to similar adjustments for other insurers.
- Future Outlook: Elevance argues that all insurers should be treated under the same rules post-rating release rather than allowing company-specific adjustments, and the outcome of this lawsuit could significantly influence the future earnings growth of insurers heavily reliant on Medicare Advantage.
See More
Investors Must Maintain Emotional Neutrality
- Investor Mindset: Robert Kiyosaki emphasizes that successful business owners and investors must maintain emotional neutrality towards winning and losing, viewing these as mere parts of the game, which helps in staying rational and patient in volatile markets.
- Twist Bioscience Performance: Twist Bioscience reported strong revenue performance for fiscal year 2025 and the first half of fiscal 2026, with third-quarter revenue expected to reach approximately $114 million to $115 million, reflecting a year-over-year growth of about 19%, showcasing its sustained growth potential in synthetic biology.
- Biodesix Clinical Validation: Biodesix's Nodify CDT test demonstrated strong performance in the largest clinical validation study for lung nodule biomarkers, with financial results for Q2 2026 expected to further boost stock prices, highlighting its leading position in early lung cancer diagnosis.
- Mirum Pharmaceuticals Progress: Mirum Pharmaceuticals' strong Q1 2026 results and the anticipated FDA decision on Zilurgisertib indicate its innovative capabilities in rare disease treatments and market confidence, which are expected to drive future stock performance.
See More
Biodesix Shares Surge 10.5% on Price Target Upgrade
- Stock Surge: Biodesix shares rose 10.5% to $16.81 in the last trading session, with trading volume significantly above average, indicating strong investor optimism.
- Price Target Upgrade: Canaccord Genuity raised Biodesix's price target from $22.00 to $27.00 while maintaining a 'Buy' rating, further fueling the stock's upward momentum.
- Financial Expectations: Biodesix is expected to report a quarterly loss of $0.85 per share, reflecting a year-over-year increase of 46.9%, while revenues are projected at $26.1 million, up 30.4%, showcasing robust growth in revenue.
- Earnings Estimate Revision: Over the past 30 days, the consensus EPS estimate for Biodesix has been revised 4% higher, and such positive revisions typically correlate with stock price appreciation, indicating market confidence in its future performance.
See More
Biodesix to Participate in Three Upcoming Investor Conferences
- Conference Schedule: Biodesix will participate in three investor conferences, including the Craig-Hallum 23rd Annual Institutional Investor Conference, William Blair 46th Annual Growth Stock Conference, and TD Cowen Annual Tools/Dx Revolution, held in Minneapolis, Chicago, and Dana Point respectively, showcasing the company's leadership in diagnostic solutions.
- Meeting Format: At the Craig-Hallum conference, Biodesix will conduct one-on-one meetings, while at the William Blair conference, it will feature a presentation and one-on-one meetings, aimed at attracting more investor interest in the company's growth potential through its innovative lung disease diagnostic tests.
- Live Webcast: Biodesix will provide a live webcast and replay of the conference presentations on the
See More
Biodesix to Present New Data at ATS Meeting
- Clinical Data Presentation: Biodesix will showcase real-world clinical and economic data related to Nodify Lung® testing at the 2026 American Thoracic Society Annual Meeting, further promoting the adoption of its blood-based tests for early lung cancer detection.
- Risk Stratification Benefits: CEO Scott Hutton emphasized the clinical value and economic advantages of Nodify Lung® testing in lung nodule management, encouraging more hospitals to adopt this technology to improve patient care and outcomes.
- Multiple Research Highlights: The meeting will feature several studies, including the impact of blood-based autoantibody tests on lung nodule risk assessment and the effects of a combined lung cancer identification program in community hospitals, demonstrating the practical application value of these tests.
- Exhibit Information: Biodesix will have Booth #1327 at the conference, showcasing its diagnostic solutions to attendees, thereby enhancing brand visibility and fostering potential collaboration opportunities.
See More
Biodesix Reports Strong Q1 2026 Earnings with Revenue Growth and Margin Expansion
- Significant Revenue Growth: Biodesix reported total revenue of $25.6 million for Q1, reflecting a 42% year-over-year increase, indicating substantial progress towards profitability, with full-year revenue guidance raised to $108 million to $114 million, showcasing strong market demand and sales expansion strategies.
- Strong Diagnostic Testing Performance: Diagnostic testing revenue reached $22.3 million, growing 37%, with test volumes increasing by 29% year-over-year, and primary care tests now accounting for 15% of total tests, demonstrating the company's success in expanding market share and enhancing its customer base.
- Clinical Evidence Driving Commercialization: Biodesix published the largest lung nodule biomarker clinical validation study involving over 1,100 patients, showing consistently high specificity for the Nodify CDT test across various risk factors, which bolstered market confidence in its products and facilitated sales growth.
- Operational Efficiency Improvement: The company reported a gross margin of 84%, including a one-time recovery of $0.4 million, and 82% excluding this recovery, indicating that Biodesix is making strides towards sustainable profitability through scale effects and cost control.
See More
Elevance Health Sues CMS Over Medicare Advantage Ratings
- Lawsuit Background: Elevance Health has filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS), alleging unfair adjustments to a competitor's Medicare Advantage Star Ratings after finalization, claiming this created an uneven competitive landscape.
- Financial Impact: Elevance estimates that the disputed CMS decision cost it approximately $115 million in Medicare Advantage quality bonus payments, directly affecting its financial performance and market competitiveness.
- Industry Implications: Should the court side with Elevance, CMS may be compelled to revisit its ratings process, potentially impacting payments and competitive positioning across the industry, which could lead to similar adjustments for other insurers.
- Future Outlook: Elevance argues that all insurers should be treated under the same rules post-rating release rather than allowing company-specific adjustments, and the outcome of this lawsuit could significantly influence the future earnings growth of insurers heavily reliant on Medicare Advantage.
See More
Investors Must Maintain Emotional Neutrality
- Investor Mindset: Robert Kiyosaki emphasizes that successful business owners and investors must maintain emotional neutrality towards winning and losing, viewing these as mere parts of the game, which helps in staying rational and patient in volatile markets.
- Twist Bioscience Performance: Twist Bioscience reported strong revenue performance for fiscal year 2025 and the first half of fiscal 2026, with third-quarter revenue expected to reach approximately $114 million to $115 million, reflecting a year-over-year growth of about 19%, showcasing its sustained growth potential in synthetic biology.
- Biodesix Clinical Validation: Biodesix's Nodify CDT test demonstrated strong performance in the largest clinical validation study for lung nodule biomarkers, with financial results for Q2 2026 expected to further boost stock prices, highlighting its leading position in early lung cancer diagnosis.
- Mirum Pharmaceuticals Progress: Mirum Pharmaceuticals' strong Q1 2026 results and the anticipated FDA decision on Zilurgisertib indicate its innovative capabilities in rare disease treatments and market confidence, which are expected to drive future stock performance.
See More
Biodesix Shares Surge 10.5% on Price Target Upgrade
- Stock Surge: Biodesix shares rose 10.5% to $16.81 in the last trading session, with trading volume significantly above average, indicating strong investor optimism.
- Price Target Upgrade: Canaccord Genuity raised Biodesix's price target from $22.00 to $27.00 while maintaining a 'Buy' rating, further fueling the stock's upward momentum.
- Financial Expectations: Biodesix is expected to report a quarterly loss of $0.85 per share, reflecting a year-over-year increase of 46.9%, while revenues are projected at $26.1 million, up 30.4%, showcasing robust growth in revenue.
- Earnings Estimate Revision: Over the past 30 days, the consensus EPS estimate for Biodesix has been revised 4% higher, and such positive revisions typically correlate with stock price appreciation, indicating market confidence in its future performance.
See More
Biodesix to Participate in Three Upcoming Investor Conferences
- Conference Schedule: Biodesix will participate in three investor conferences, including the Craig-Hallum 23rd Annual Institutional Investor Conference, William Blair 46th Annual Growth Stock Conference, and TD Cowen Annual Tools/Dx Revolution, held in Minneapolis, Chicago, and Dana Point respectively, showcasing the company's leadership in diagnostic solutions.
- Meeting Format: At the Craig-Hallum conference, Biodesix will conduct one-on-one meetings, while at the William Blair conference, it will feature a presentation and one-on-one meetings, aimed at attracting more investor interest in the company's growth potential through its innovative lung disease diagnostic tests.
- Live Webcast: Biodesix will provide a live webcast and replay of the conference presentations on the
See More
Biodesix to Present New Data at ATS Meeting
- Clinical Data Presentation: Biodesix will showcase real-world clinical and economic data related to Nodify Lung® testing at the 2026 American Thoracic Society Annual Meeting, further promoting the adoption of its blood-based tests for early lung cancer detection.
- Risk Stratification Benefits: CEO Scott Hutton emphasized the clinical value and economic advantages of Nodify Lung® testing in lung nodule management, encouraging more hospitals to adopt this technology to improve patient care and outcomes.
- Multiple Research Highlights: The meeting will feature several studies, including the impact of blood-based autoantibody tests on lung nodule risk assessment and the effects of a combined lung cancer identification program in community hospitals, demonstrating the practical application value of these tests.
- Exhibit Information: Biodesix will have Booth #1327 at the conference, showcasing its diagnostic solutions to attendees, thereby enhancing brand visibility and fostering potential collaboration opportunities.
See More
Biodesix Reports Strong Q1 2026 Earnings with Revenue Growth and Margin Expansion
- Significant Revenue Growth: Biodesix reported total revenue of $25.6 million for Q1, reflecting a 42% year-over-year increase, indicating substantial progress towards profitability, with full-year revenue guidance raised to $108 million to $114 million, showcasing strong market demand and sales expansion strategies.
- Strong Diagnostic Testing Performance: Diagnostic testing revenue reached $22.3 million, growing 37%, with test volumes increasing by 29% year-over-year, and primary care tests now accounting for 15% of total tests, demonstrating the company's success in expanding market share and enhancing its customer base.
- Clinical Evidence Driving Commercialization: Biodesix published the largest lung nodule biomarker clinical validation study involving over 1,100 patients, showing consistently high specificity for the Nodify CDT test across various risk factors, which bolstered market confidence in its products and facilitated sales growth.
- Operational Efficiency Improvement: The company reported a gross margin of 84%, including a one-time recovery of $0.4 million, and 82% excluding this recovery, indicating that Biodesix is making strides towards sustainable profitability through scale effects and cost control.
See More
